Are you prepared to answer tough questions about your products?
Life sciences companies are confronting the impact of the Inflation Reduction Act (IRA) of 2022, especially the Centers for Medicare & Medicaid Services’ (CMS) drug price negotiation program. As you enter negotiations and prepare evidence for CMS, it’s important to think about the current state of your products. Using only clinical trial data that’s over 10 years old won’t work. To build your case with stakeholders, you need:
- Timely, real-world information on product use and performance in the Medicare population
- The ability to describe the value of that evidence
You should be able to answer a range of questions about your products and pipeline strategy in a post-IRA world. Read this overview to see how real-world data and evidence, research consulting and financial modelling services can help strengthen your product value story.
Reassess the Inflation Reduction Act with evidence in mind
Cut through the noise of the Inflation Reduction Act of 2022 with key points aimed to help life sciences leaders leverage impactful data.
Integrated RWD: the key to accelerating innovation
To maximize the value of clinical innovations, you need dimensional, robust data. Learn about leveraging integrated cost and clinical data.
6 guiding steps for selecting a fit-for-purpose data set
Using RWD that are not fit for purpose can waste time and money. Review 6 simple steps to guide your research towards the right data.